Drug General Information
Drug ID	D07PNT
Former ID	DCL000011
Drug Name	XL999
Indication	Advanced malignancies [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[537114]
Therapeutic Class	Anticancer Agents
Company	Exelixis
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Vascular endothelial growth factor receptor 2	Target Info	Inhibitor	[536402]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	Cytokine-cytokine receptor interaction
	Endocytosis
	PI3K-Akt signaling pathway
	VEGF signaling pathway
	Focal adhesion
	Proteoglycans in cancer
NetPath Pathway	IL2 Signaling Pathway
PANTHER Pathway	Angiogenesis
	VEGF signaling pathway
Pathway Interaction Database	HIF-2-alpha transcription factor network
	Beta3 integrin cell surface interactions
	Signaling events mediated by TCPTP
	SHP2 signaling
	S1P1 pathway
	VEGF and VEGFR signaling network
	Integrins in angiogenesis
	Signaling events mediated by VEGFR1 and VEGFR2
	Notch-mediated HES/HEY network
Reactome	Neurophilin interactions with VEGF and VEGFR
	VEGF binds to VEGFR leading to receptor dimerization
	Integrin cell surface interactions
	EPHA-mediated growth cone collapse
	VEGFA-VEGFR2 Pathway
	VEGFR2 mediated cell proliferation
WikiPathways	Focal Adhesion
	Nifedipine Activity
	Cardiac Progenitor Differentiation
	Signaling by VEGF
	Angiogenesis
References
Ref 537114	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
Ref 536402	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.